Co‑pay accumulators risk

Co-pay accumulator and maximizer programs can leave insured patients with the full bill for expensive medicines after coupon help runs out. (ajmc.com) A co-pay accumulator lets a manufacturer coupon lower the price at the pharmacy counter but does not count that coupon toward the patient’s deductible or annual out-of-pocket limit. KFF said patients can then face large bills once the coupon is exhausted. (kff.org) A co-pay maximizer works differently: it spreads a coupon’s value across the year, often keeping monthly payments lower, but it still keeps that assistance from helping the patient reach the plan’s cost-sharing limit. A 2024 Journal of Managed Care & Specialty Pharmacy primer said both models reduce plan spending while increasing complexity for patients trying to start or stay on treatment. (jmcp.org) At AMCP 2026, Patty Taddei-Allen said these designs are showing up alongside alternative funding programs, which remove some drugs from coverage and push patients toward outside charity aid. Avalere Health said alternative funding programs typically direct patients to charitable assistance programs originally created for uninsured people. (ajmc.com) (advisory.avalerehealth.com) The pressure lands hardest on people taking specialty drugs for cancer, rheumatoid arthritis, diabetes, HIV, and other chronic conditions with few substitutes. KFF said plans are more likely to use coinsurance, not flat co-pays, on these higher-cost drugs, which raises the patient share. (kff.org) The access problem is no longer niche. Avalere said more than 60% of the accumulator, maximizer, and alternative funding programs in its 2025 payer survey had been implemented within the previous four years, and the survey found all three were widely used and increasing. (advisory.avalerehealth.com) State lawmakers have been trying to limit the practice. The National Conference of State Legislatures said that, as of 2025, at least 25 states, Washington, D.C., and Puerto Rico had enacted laws requiring insurers or pharmacy benefit managers to count assistance paid on a patient’s behalf toward cost-sharing in at least some plans. (ncsl.org) Federal policy is still unsettled. NCSL said a 2023 court ruling barred insurers under federal regulation from using accumulators for drugs without generic equivalents, while broader rulemaking has lagged. (ncsl.org) Pharmacy benefit managers defend accumulators and maximizers as tools to blunt the effect of drugmaker coupons on benefit design and premiums. The Pharmaceutical Care Management Association says plans need these programs to constrain high drug costs, while patient advocates and clinicians say the result can be missed fills, treatment delays, and abrupt drop-off from care. (pcmanet.org) (managedhealthcareexecutive.com) The basic fight is over who gets the value of the coupon: the patient at the pharmacy counter, or the plan after the claim is paid. For patients who thought coupon help was moving them toward their deductible, the answer can arrive as a midyear bill they did not expect. (kff.org)